Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Neuroimmunomodulation|August 20, 2010
CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosisAdam Szczuciński, Jacek LosyPrzeglad Epidemiologiczny|August 17, 2006
[Infectious agents in the pathogenesis of multiple sclerosis]Adam Szczuciński, Jacek LosyActa Neurologica Scandinavica|February 14, 2007
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapiesAdam Szczuciński, Jacek LosyFolia Neuropathologica|May 4, 2004
Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosisAdam Szczuciński, Jacek LosyEuropean Neurology|September 11, 2007
CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisoloneAdam Szczuciński, Alicja Kalinowska, Jacek LosyNeurologia I Neurochirurgia Polska|May 14, 2014
Heterogeneous phenotypic manifestations of maternally inherited deafness associated with the mitochondrial A3243G mutation. Case reportMagdalena Hoptasz, Adam Szczuciński, Jacek LosyJournal of the Neurological Sciences|October 16, 2010
Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patientsAlicja Kalinowska-Łyszczarz, Adam Szczuciński, Mikołaj A Pawlak, et al.Pharmacological Reports : PR|January 16, 2007
Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patientsGrazyna Michałowska-Wender, Jacek Losy, Adam Szczuciński, et al.Pageof 1